Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 9:8:212574.
doi: 10.7573/dic.212574. eCollection 2019.

Venetoclax: evidence to date and clinical potential

Luis Miguel Juárez-Salcedo  1 , Viraj Desai  2 , Samir Dalia  3
Affiliations
Review

Venetoclax: evidence to date and clinical potential

Luis Miguel Juárez-Salcedo et al. Drugs Context. .

Abstract

The emergence of targeted therapy for patients with hematological diseases has permanently altered the therapeutic landscape. Immunochemotherapy regimes are now more and more being replaced by targeted therapies due to superior efficacy and better safety profiles. However, evolution and selection of subclones with continuous treatment leads to disease relapse and resistance toward these novel drugs. Venetoclax, the highly selective BCL-2 inhibitor (ABT-199), has an acceptable safety profile. To date, it has been approved for the treatment of first-line and relapsed/refractory chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, extension of indications can be expected in monotherapy and in combination regimens with promising outcomes in other hematological diseases. In this article, we describe the mechanism of action that stands behind the efficacy of venetoclax and provide a summary of available results from clinical trials.

Keywords: cancer drugs; leukemia; lymphoma; venetoclax.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at http://www.drugsincontext.com/wp-content/uploads/2019/09/dic.212574-COI.pdf

References

    1. World Cancer Research Fund International. [Last accessed July 19, 2019]. Available at https://www.wcrf.org/int/cancer-facts-figures/worldwide-data.
    1. Drugs.com. Venclexta Approval History. 2019. [Last accessed July 19, 2019]. Available at https://www.drugs.com/history/venclexta.html.
    1. European Medicines Agency. Venclyxto (venetoclax) EPAR: an overview of Venclyxto and why it is authorised in the EU. 2018. [Last accessed July 19, 2019]. https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto.
    1. Deeks ED. Venetoclax: First global approval. Drugs. 2016;76:979–987. doi: 10.1007/s40265-016-0596-x. - DOI - PubMed
    1. Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: targeting BCL2 in hematological cancers. Recent Results Cancer Res. 2018;212:215–242. doi: 10.1007/978-3-319-91439-8_11. - DOI - PubMed